DrugPatentWatch Database Preview

CABERGOLINE Drug Profile

  Purchase this report

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Cabergoline patents expire, and what generic alternatives are available?

Cabergoline is a drug marketed by Actavis Labs Fl Inc, Apotex Corp, Impax Labs Inc, Ingenus Pharms Llc, Ivax Sub Teva Pharms, Mylan Pharms Inc, and Par Pharm. and is included in seven NDAs.

The generic ingredient in CABERGOLINE is cabergoline. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cabergoline profile page.

Summary for CABERGOLINE

US Patents:	0
Applicants:	7
NDAs:	7
Suppliers / Packagers:	4
Bulk Api Vendors:	39
Clinical Trials:	43
Patent Applications:	2,517
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for CABERGOLINE
DailyMed Link:	CABERGOLINE at DailyMed

Pharmacology for CABERGOLINE

Ingredient-type	Ergolines
Drug Class	Ergot Derivative

Synonyms for CABERGOLINE

(6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide

(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide

(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide

(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide

(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide

1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea

1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea

1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea

1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea

1-[3-(DIMETHYLAMINO)PROPYL]-3-ETHYL-1-[(2R,4R,7R)-6-(PROP-2-EN-1-YL)-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(15),9,12(16),13-TETRAENE-4-CARBONYL]UREA

1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea

1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0;{2,7}.0;{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea

1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate

1-Ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'beta-carbonyl)urea

1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea

409C907

6-allyl-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-ergoline-8beta-carboxamide

81409-90-7

85329-89-1 (diphosphate)

AB01275484-01

AC-26126

AC1L1HO0

AC1Q5OQ0

AKOS015961587

AN-36255

BC207368

BDBM50426497

BIDD:GT0775

BRD-K86882815-001-01-6

BRN 6020775

C08187

C26H37N5O2

Cabaser

Cabaser (TN)

Cabaseril

Cabergolina

Cabergolina [Spanish]

Cabergoline (JAN/USAN/INN)

Cabergoline [USAN:BAN:INN]

Cabergoline, >=98% (HPLC)

Cabergoline, European Pharmacopoeia (EP) Reference Standard

Cabergoline, United States Pharmacopeia (USP) Reference Standard

Cabergolinum

Cabergolinum [Latin]

Caberlin

CAS-81409-90-7

CG-101

CHEBI:3286

CHEMBL1201087

CTK8F8406

D00987

D04EGX

DB00248

Dostinex

Dostinex (TN)

DR002797

DSSTox_CID_2719

DSSTox_GSID_22719

DSSTox_RID_76698

DTXSID6022719

Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-

Ergoline-8beta-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-

FCE-21336

FT-0081285

FT-0650562

Galastop

GTPL37

HMS2090A09

K450

KORNTPPJEAJQIU-KJXAQDMKSA-N

LL60K9J05T

LS-64370

MFCD00867887

MolPort-003-845-557

N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-allyl-ergoline-8beta-carboxamide

NCGC00167821-01

NCGC00344544-01

PL070592

SC-19831

SCHEMBL42292

Sogilen

SR-05000001493

SR-05000001493-2

Tox21_112589

Tox21_112589_1

UNII-LL60K9J05T

ZINC3800008

US Patents and Regulatory Information for CABERGOLINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Fl Inc	CABERGOLINE	cabergoline	TABLET;ORAL	078035-001	Apr 21, 2008	AB	RX	No	No
Par Pharm	CABERGOLINE	cabergoline	TABLET;ORAL	076310-001	Dec 29, 2005	AB	RX	No	Yes
Ingenus Pharms Llc	CABERGOLINE	cabergoline	TABLET;ORAL	204735-001	Aug 1, 2018	AB	RX	No	No
Apotex Corp	CABERGOLINE	cabergoline	TABLET;ORAL	201503-001	Mar 8, 2013		DISCN	No	No
Impax Labs Inc	CABERGOLINE	cabergoline	TABLET;ORAL	077843-001	Jul 3, 2007		DISCN	No	No

  Purchase this report

see a sample report or, see our see our flat-rate plans

  Purchase this report

see a sample report or, see our see our flat-rate plans